Applying TCR Mimic Antibodies in T-Cell Therapy to Achieve Durable & Persistent Clinical Responses

• Sharing developments in an ongoing phase 1 trial and key learnings from the clinic
• Explaining how TCR mimic armed T-cell therapy enables dual activation of CD4 and CD8 T-cells
• Discuss why CD4 engagement is critical for long-term efficacy

New Data

Speakers:

Cheng liu

CEO

Eureka Therapeutics